Publications by authors named "Richard Baum"

Claim this Profile
P
Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH study.
Giulia Santo, Margarida Rodrigues, Diana Paez, Olga Morozova, Levent Kabasakal, Richard P Baum

Theranostics· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intra-arterial peptide receptor radionuclide therapy (IA-PRRT) in patients with SSTR-expressing neuroendocrine neoplasms: short- and long-term safety and efficacy for up to 13 years.
Jingjing Zhang, Birger Mensel, Richard P Baum

Theranostics· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current status of FAP therapy in solid tumors.
Sophie C Siegmund, Emil Novruzov, Eduards Mamlins, Yuriko Mori, Sven Otto, Richard P Baum

Semin Nucl Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Guiding principles on the education and practice of theranostics.
Thomas N B Pascual, Diana Paez, Andrei Iagaru, Gopi Gnanasegaran, Sze Ting Lee, Richard P Baum

Eur J Nucl Med Mol Imaging· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review and meta-analysis of the efficacy and safety of [Lu]Lu-edotreotide ([Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors.
Richard P Baum, Julia G Fricke, Tristan Ruhwedel, Holger Amthauer, Erika Patricia Azorin-Vega

J Neuroendocrinol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TANDEM Peptide Receptor Radionuclide Therapy Using [ 225 Ac]Ac-/[ 177 Lu]Lu-DOTA-LM3 in a Patient With Parotid Gland Metastasis From Pancreatic Neuroendocrine Neoplasm.
Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant, Richard P Baum

Clin Nucl Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-utility analysis of Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany.
Carolin Brinkmann, Richard P Baum, Tom Stargardt

Eur J Nucl Med Mol Imaging· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [225Ac]Ac-DOTA-LM3.
Elisabetta Perrone, Shagufta Shaheen, Pamela L Kunz, Heather C Henri, Richard P Baum

Clin Nucl Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival.
Elisabetta Perrone, Maria Lucia Calcagni, Lucia Leccisotti, Roberto Moretti, Kriti Ghai, Richard Paul Baum

Cancers (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axillary Skin Fibroblast Activation Protein Uptake After Chemo-immunotherapy on PET/CT and SPET/CT: A Mere Coincidence or Causality?
Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant, Maurizio Podda, Richard P Baum

Clin Nucl Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ICPO Forum 2025: advancing theranostics in precision oncology.
Richard Paul Baum, Odile Jaume

Lancet Reg Health Eur· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy.
Aviral Singh, Sebastian Sanduleanu, Harshad R Kulkarni, Thomas Langbein, Philippe Lambin, Richard P Baum

Front Endocrinol (Lausanne)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma.
Jingjing Zhang, Deling Li, Mengqi Shi, Vivianne Jakobsson, Wang Jia, Richard P Baum

Clin Nucl Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Influence of Radioligand Therapy on Immunogenicity Against SARS-CoV-2-A Retrospective Single-Arm Cohort Study of Metastatic Prostate Cancer Patients Receiving PSMA Radioligand Therapy.
Carsten S Kramer, Aleksandr Eismant, Aditi Mishra, Corinna Müller, Christian Landvogt, Richard P Baum

Cancers (Basel)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of an optimized, potential kit-type, SSTR antagonist Ga-DATA-LM4 in patients with metastatic neuroendocrine tumors.
Jingjing Zhang, Lukas Greifenstein, Vivianne Jakobsson, Elcin Zan, Andre Klega, Richard P Baum

Theranostics· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing theranostics chatbots with context-augmented large language models.
Pia Koller, Christoph Clement, Albert van Eijk, Robert Seifert, Jingjing Zhang, Richard Baum

Theranostics· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during Lu/Ac treatment in neuroendocrine tumors and metastatic prostate cancer.
Habibollah Dadgar, Ali Pashazadeh, Nasim Norouzbeigi, Majid Assadi, Batool Al-Balooshi, Richard P Baum

Theranostics· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Survival Outcomes of [Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [Ac]Ac-/[Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer.
Elisabetta Perrone, Alessandro Giordano, Maria Lucia Calcagni, Lucia Leccisotti, Roberto Moretti, Richard P Baum

Cancers (Basel)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders.
Masha Maharaj, Elisabetta Perrone, Ralph M Wirtz, Lucille Heslop, Trisha Govender, Richard P Baum

Cancers (Basel)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in the Management and Outcomes of Neuroendocrine Liver Metastases: A Three-decade, Multi-centre Observational Cohort Study.
Andrea Frilling, Ashley K Clift, Daniel Kaemmerer, Kira C Steinkraus, Joerg Schrader, Richard P Baum

Ann Surg· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extraordinary therapeutic effect of PSMA radioligand therapy in treatment-refractory progressive metastatic prostate cancer with the transketolase inhibitor benfo-oxythiamine as a radiosensitizer-A case report.
Carsten S Kramer, Jingjing Zhang, Richard P Baum

Front Med (Lausanne)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Response to Molecular Radiotherapy with Lu-DOTATOC: Predictive Value of Blood Cell Counts for Therapy Outcome.
Andreas Kluge, Richard P Baum, Norman Bitterlich, Harshad R Kulkarni, Ulrike Schorr-Neufing

Cancer Biother Radiopharm· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
177Lu-PSMA radioligand therapy for isolated bilateral adrenal metastases from prostate cancer.
Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant, Kornelia Konz, Richard P Baum

Acta Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides.
Richard P Baum, Emil Novruzov, Tianzhi Zhao, Lukas Greifenstein, Vivianne Jakobsson

Semin Nucl Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer.
Finn Edler von Eyben, Irene Virgolini, Richard Baum

Cancers (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis